NCCM
TOVX icon

Nine Chapters Capital Management’s Theriva Biologics TOVX Stock Holding History

Nine Chapters Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$16K Buy
2
+1
+100% +$5.78K 0.04% 151
2017
Q2 		$7K Buy
+1
New +$4.98K 0.07% 56

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Nine Chapters Capital Management's TOVX Position: Q3 2017 in Review

Nine Chapters Capital Management increased its Theriva Biologics (TOVX) stake by 100% in Q3 2017, buying an estimated $5.78K and bringing the position to 2 shares worth $16K. The position accounts for 0.04% of the portfolio, ranked #151.

Nine Chapters Capital Management first reported a position in TOVX in Q2 2017 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold TOVX as of Q3 2017.

  • Nine Chapters Capital Management held 2 shares of Theriva Biologics worth $16K as of Q3 2017.
  • Nine Chapters Capital Management bought 1 Theriva Biologics share in Q3 2017, an estimated $5.78K.
  • Theriva Biologics made up 0.04% of Nine Chapters Capital Management's portfolio in Q3 2017, its #151 holding.
  • Nine Chapters Capital Management first reported a position in Theriva Biologics in Q2 2017 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.